Retraction
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Paper Information
Record ID:
58036
Author(s):
Journal:
Publication Date:
September 04, 2015
Retraction Date:
October 22, 2024
(1.1 year years ago)
Subjects:
Institutions:
- LeBow Institute for Myeloma Therapeutics and the Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Department of Hematology, Myeloma and Lymphoma Centre, Chang Zheng Hospital, The Second Military Medical University, Shanghai, China
- Sanofi Oncology, Cambridge, MA, USA
- Institute of Hematology, CAMS & PUMC, Tianjin, China
Countries:
Article Type:
Publisher:
Springer - Nature Publishing Group
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1038/s41375-024-02443-zAdditional Notes:
see also: https://pubpeer.com/publications/BE119832A5B1091025C04244B43F5D
Citations (213)
213
Total Citations5
Post-Retraction(2.3%)
208
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
2
Within 30 days
5
Within 1 year
0
After 2+ years
204
Days since retraction (latest)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. (92 authors)
The Lancet
Published: Jun 2021
322 citations
322 citations
1239 days before retraction
Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Hiroko Nishida
Cancers
Open Access
Published: May 2021
17 citations
17 citations
1240 days before retraction
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
Saad Z. Usmani, Chatchada Karanes, William Bensinger et al. (14 authors)
Leukemia
Open Access
Published: May 2021
18 citations
18 citations
1243 days before retraction
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
Simon J. Harrison, Aurore Perrot, Adrián Alegre et al. (18 authors)
British Journal of Haematology
Open Access
Published: May 2021
41 citations
41 citations
1246 days before retraction
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
Joseph Mıkhael, Karim Belhadj‐Merzoug, Cyrille Hulin et al. (21 authors)
Blood Cancer Journal
Open Access
Published: May 2021
77 citations
77 citations
1259 days before retraction
An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma
Anna Piggin, H. Miles Prince
Expert Review of Hematology
Published: May 2021
1267 days before retraction
Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
Radowan Elnair, Sarah A. Holstein
Drugs
Published: Apr 2021
13 citations
13 citations
1282 days before retraction
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
Sara Bringhen, Luděk Pour, Vladimir Vorobyev et al. (15 authors)
Leukemia Research
Open Access
Published: Mar 2021
23 citations
23 citations
1303 days before retraction
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma
Marc Braunstein, Jonathan Weltz, Faith E. Davies
Expert Review of Hematology
Published: Mar 2021
12 citations
12 citations
1306 days before retraction
Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression
Andrea Díaz-Tejedor, Mauro Lorenzo-Mohamed, Noemí Puig et al. (7 authors)
Cancers
Open Access
Published: Mar 2021
41 citations
41 citations
1315 days before retraction
Boosting Immunity against Multiple Myeloma
Raquel Lopes, Bruna Velosa Ferreira, Joana Caetano et al. (6 authors)
Cancers
Open Access
Published: Mar 2021
9 citations
9 citations
1321 days before retraction
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Leona Yamamoto, Nicola Amodio, Annamaria Gullà et al. (4 authors)
Frontiers in Oncology
Open Access
Published: Jan 2021
34 citations
34 citations
1364 days before retraction
IFN-γ and CD38 in Hyperprogressive Cancer Development
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi et al. (9 authors)
Cancers
Open Access
Published: Jan 2021
25 citations
25 citations
1376 days before retraction
Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma
Michelle Kinder, Nizar J. Bahlis, Fabio Malavasi et al. (10 authors)
Haematologica
Open Access
Published: Jan 2021
29 citations
29 citations
1377 days before retraction
Bones of Contention: Reflections on Osteoarchaeology and the Baltic Region
László Bartosiewicz
Archaeologia Lituana
Open Access
Published: Dec 2020
1 citation
1 citation
1394 days before retraction
Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma
H. N. Abramson
IntechOpen eBooks
Open Access
Published: Nov 2020
1 citation
1 citation
1446 days before retraction
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Tengteng Yu, Bharat K. R. Chaganty, Liang Lin et al. (23 authors)
Blood Cancer Journal
Open Access
Published: Nov 2020
38 citations
38 citations
1450 days before retraction
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
Mattia D’Agostino, Salvatore Innorcia, Mario Boccadoro et al. (4 authors)
International Journal of Molecular Sciences
Open Access
Published: Nov 2020
20 citations
20 citations
1451 days before retraction
The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Josée Golay, Ronald P. Taylor
Antibodies
Open Access
Published: Oct 2020
81 citations
81 citations
1455 days before retraction
Isatuximab for the treatment of relapsed/refractory multiple myeloma
Paul G. Richardson, Meral Beksaç, Ivan Špıčka et al. (4 authors)
Expert Opinion on Biological Therapy
Open Access
Published: Oct 2020
33 citations
33 citations
1455 days before retraction
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios Α. Dimopoulos, Sara Galimberti, P. Anttila et al. (17 authors)
Blood
Open Access
Published: Oct 2020
74 citations
74 citations
1463 days before retraction
Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients
Jean‐Baptiste Fau, Raouf El‐Cheikh, Claire Brillac et al. (8 authors)
CPT Pharmacometrics & Systems Pharmacology
Open Access
Published: Oct 2020
23 citations
23 citations
1477 days before retraction
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
Kazutaka Sunami, Kenshi Suzuki, Masaki Ri et al. (21 authors)
Cancer Science
Open Access
Published: Sep 2020
15 citations
15 citations
1488 days before retraction
Emerging immunotherapies in multiple myeloma
Urvi A. Shah, Sham Mailankody
BMJ
Open Access
Published: Sep 2020
120 citations
120 citations
1492 days before retraction
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
Paola Storti, Federica Costa, Valentina Marchica et al. (8 authors)
Journal of Clinical Medicine
Open Access
Published: Sep 2020
7 citations
7 citations
1509 days before retraction
CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers
Ying Jiao, Ming Yi, Linping Xu et al. (7 authors)
Expert Opinion on Investigational Drugs
Published: Aug 2020
23 citations
23 citations
1523 days before retraction
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
Chen Zhu, Zhili Song, Anlai Wang et al. (18 authors)
Frontiers in Immunology
Open Access
Published: Aug 2020
100 citations
100 citations
1530 days before retraction
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Fredrik Schjesvold, Paul G. Richardson, Thierry Façon et al. (16 authors)
Haematologica
Open Access
Published: Jun 2020
27 citations
27 citations
1580 days before retraction
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
Dario Roccatello, Roberta Fenoglio, Savino Sciascia et al. (9 authors)
International Journal of Molecular Sciences
Open Access
Published: Jun 2020
24 citations
24 citations
1595 days before retraction
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
Matthew Ho, Chia Yin Goh, Ashish Patel et al. (7 authors)
Clinical Lymphoma Myeloma & Leukemia
Published: Jun 2020
32 citations
32 citations
1598 days before retraction
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
Shih‐Feng Cho, Liang Lin, Lijie Xing et al. (7 authors)
Cancers
Open Access
Published: Jun 2020
50 citations
50 citations
1600 days before retraction
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios Α. Dimopoulos, Xavier Leleu, Philippe Moreau et al. (14 authors)
Leukemia
Open Access
Published: May 2020
64 citations
64 citations
1614 days before retraction
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Joseph Mıkhael, Joshua Richter, Ravi Vij et al. (19 authors)
Leukemia
Open Access
Published: May 2020
51 citations
51 citations
1622 days before retraction
Isatuximab: First Approval
Sohita Dhillon
Drugs
Published: Apr 2020
67 citations
67 citations
1638 days before retraction
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Laurens E. Franssen, Claudia A.M. Stege, Sonja Zweegman et al. (5 authors)
Journal of Clinical Medicine
Open Access
Published: Apr 2020
43 citations
43 citations
1644 days before retraction
Oxidative damage of lysosomes in regulated cell death systems: Pathophysiology and pharmacologic interventions
Pandian Nagakannan, Parisa Tabeshmehr, Eftekhar Eftekharpour
Free Radical Biology and Medicine
Published: Apr 2020
31 citations
31 citations
1662 days before retraction
Evolving Role of Daratumumab: From Backbencher to Frontline Agent
Ankur Jain, Karthik Ramasamy
Clinical Lymphoma Myeloma & Leukemia
Published: Apr 2020
17 citations
17 citations
1664 days before retraction
Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date
Joshua Richter, Larysa Sanchez, Santiago Thibaud
Seminars in Oncology
Published: Apr 2020
20 citations
20 citations
1665 days before retraction
Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma
Yi Hu, Huimin Liu, Chuanfeng Fang et al. (22 authors)
Cancer Research
Open Access
Published: Mar 2020
35 citations
35 citations
1678 days before retraction
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
Lijie Xing, Liang Lin, Tengteng Yu et al. (12 authors)
Leukemia
Open Access
Published: Feb 2020
57 citations
57 citations
1712 days before retraction
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Carla Monteiro Pinto, Rui Bergantim, Hugo R. Caires et al. (6 authors)
Cancers
Open Access
Published: Feb 2020
197 citations
197 citations
1716 days before retraction
The Lysosomal Membrane Protein Lamp2 Alleviates Lysosomal Cell Death by Promoting Autophagic Flux in Ischemic Cardiomyocytes
Lin Cui, Liping Zhao, Jingying Ye et al. (10 authors)
Frontiers in Cell and Developmental Biology
Open Access
Published: Feb 2020
56 citations
56 citations
1719 days before retraction
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Ilaria Saltarella, Vanessa Desantis, Assunta Melaccio et al. (10 authors)
Cells
Open Access
Published: Jan 2020
103 citations
103 citations
1748 days before retraction
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Maximilian Steinhardt, Xiang Zhou, Franziska Krummenast et al. (14 authors)
International Journal of Immunopathology and Pharmacology
Open Access
Published: Jan 2020
2 citations
2 citations
1756 days before retraction
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Levin Schriewer, Kerstin Schütze, Katharina Petry et al. (24 authors)
Theranostics
Open Access
Published: Jan 2020
20 citations
20 citations
1756 days before retraction
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
Francesca Bonello, Roberto Mina, Mario Boccadoro et al. (4 authors)
Cancers
Open Access
Published: Dec 2019
46 citations
46 citations
1769 days before retraction
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Federica Costa, Benedetta Dalla Palma, Nicola Giuliani
Cells
Open Access
Published: Dec 2019
37 citations
37 citations
1775 days before retraction
Anticorps anti-CD38 dans le myélome multiple
Jérôme Moreaux
médecine/sciences
Open Access
Published: Dec 2019
2 citations
2 citations
1787 days before retraction
CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies
Fabio Morandi, Irma Airoldi, Danilo Marimpietri et al. (6 authors)
Cells
Open Access
Published: Nov 2019
70 citations
70 citations
1791 days before retraction
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Thomas G. Martin, Kathryn P. Corzo, Marielle Chiron et al. (13 authors)
Cells
Open Access
Published: Nov 2019
147 citations
147 citations
1792 days before retraction
Quick Stats
Total Citations:
213
Years Since Retraction:
1.1 year
Open Access:
Yes
Last Checked:
Jul 24, 2025